Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 29 entries
Sorted by: Best Match Show Resources per page
Esophageal carcinoma.

Postgraduate medicine

CLAGETT OT.
PMID: 14384618
Postgrad Med. 1955 Jun;17(6):438-9. doi: 10.1080/00325481.1955.11711860.

No abstract available.

Cite
CLAGETT OT. Esophageal carcinoma. Postgrad Med. 1955;17(6):438-9doi: 10.1080/00325481.1955.11711860.
CLAGETT, O. T. (1955). Esophageal carcinoma. Postgraduate medicine, 17(6), 438-9. https://doi.org/10.1080/00325481.1955.11711860
CLAGETT, O T. "Esophageal carcinoma." Postgraduate medicine vol. 17,6 (1955): 438-9. doi: https://doi.org/10.1080/00325481.1955.11711860
CLAGETT OT. Esophageal carcinoma. Postgrad Med. 1955 Jun;17(6):438-9. doi: 10.1080/00325481.1955.11711860. PMID: 14384618.
Copy Download .nbib Format: NLM
Benign tumors and cysts of the esophagus.

Transactions of the ... Annual Meeting of the American Broncho-Esophagological Association. American Broncho-Esophagological Association. Meeting

SCHMIDT HW, CLAGETT OT, HARRISON EG.
PMID: 14498736
Trans Annu Meet Am Bronchoesophagol Assoc. 1961;41:94-105.

No abstract available.

Cite
SCHMIDT HW, CLAGETT OT, HARRISON EG. Benign tumors and cysts of the esophagus. Trans Annu Meet Am Bronchoesophagol Assoc. 1961;41:94-105
SCHMIDT, H. W., CLAGETT, O. T., & HARRISON, E. G. (1961). Benign tumors and cysts of the esophagus. Transactions of the ... Annual Meeting of the American Broncho-Esophagological Association. American Broncho-Esophagological Association. Meeting, 4194-105.
SCHMIDT, H W, et al. "Benign tumors and cysts of the esophagus." Transactions of the ... Annual Meeting of the American Broncho-Esophagological Association. American Broncho-Esophagological Association. Meeting vol. 41 (1961): 94-105.
SCHMIDT HW, CLAGETT OT, HARRISON EG. Benign tumors and cysts of the esophagus. Trans Annu Meet Am Bronchoesophagol Assoc. 1961;41:94-105. PMID: 14498736.
Copy Download .nbib Format: NLM
Alveolar-cell tumors of the lung.

The Journal of thoracic surgery

GRIFFITH ER, McDONALD JR, CLAGETT OT.
PMID: 14785033
J Thorac Surg. 1950 Dec;20(6):949-60.

No abstract available.

Cite
GRIFFITH ER, McDONALD JR, CLAGETT OT. Alveolar-cell tumors of the lung. J Thorac Surg. 1950;20(6):949-60
GRIFFITH, E. R., McDONALD, J. R., & CLAGETT, O. T. (1950). Alveolar-cell tumors of the lung. The Journal of thoracic surgery, 20(6), 949-60.
GRIFFITH, E R, et al. "Alveolar-cell tumors of the lung." The Journal of thoracic surgery vol. 20,6 (1950): 949-60.
GRIFFITH ER, McDONALD JR, CLAGETT OT. Alveolar-cell tumors of the lung. J Thorac Surg. 1950 Dec;20(6):949-60. PMID: 14785033.
Copy Download .nbib Format: NLM
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ.
PMID: 33693561
Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212.

BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal...

Cite
Marconi VC, Moser C, Gavegnano C, et al. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022;74(1):95-104doi: 10.1093/cid/ciab212.
Marconi, V. C., Moser, C., Gavegnano, C., Deeks, S. G., Lederman, M. M., Overton, E. T., Tsibris, A., Hunt, P. W., Kantor, A., Sekaly, R. P., Tressler, R., Flexner, C., Hurwitz, S. J., Moisi, D., Clagett, B., Hardin, W. R., Del Rio, C., Schinazi, R. F., & Lennox, J. J. (2022). Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(1), 95-104. https://doi.org/10.1093/cid/ciab212
Marconi, Vincent C, et al. "Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 74,1 (2022): 95-104. doi: https://doi.org/10.1093/cid/ciab212
Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212. PMID: 33693561; PMCID: PMC8752257.
Copy Download .nbib Format: NLM
Recent advances in the treatment of heart disease.

The Journal of the Arkansas Medical Society

CLAGETT AH.
PMID: 13693783
J Ark Med Soc. 1960 Dec;57:267-75.

No abstract available.

Cite
CLAGETT AH. Recent advances in the treatment of heart disease. J Ark Med Soc. 1960;57:267-75
CLAGETT, A. H. (1960). Recent advances in the treatment of heart disease. The Journal of the Arkansas Medical Society, 57267-75.
CLAGETT, A H. "Recent advances in the treatment of heart disease." The Journal of the Arkansas Medical Society vol. 57 (1960): 267-75.
CLAGETT AH. Recent advances in the treatment of heart disease. J Ark Med Soc. 1960 Dec;57:267-75. PMID: 13693783.
Copy Download .nbib Format: NLM
Accuracy assessment of NLCD 2011 impervious cover data for the Chesapeake Bay region, USA.

ISPRS journal of photogrammetry and remote sensing : official publication of the International Society for Photogrammetry and Remote Sensing (ISPRS)

Wickham J, Herold N, Stehman SV, Homer CG, Xian G, Claggett P.
PMID: 30996518
ISPRS J Photogramm Remote Sens. 2018;146:151-160. doi: 10.1016/j.isprsjprs.2018.09.010.

The National Land Cover Database (NLCD) contains three eras (2001, 2006, 2011) of percentage urban impervious cover (%IC) at the native pixel size (30 m-×-30 m) of the Landsat Thematic Mapper satellite. These data are potentially valuable to environmental...

Cite
Wickham J, Herold N, Stehman SV, et al. Accuracy assessment of NLCD 2011 impervious cover data for the Chesapeake Bay region, USA. ISPRS J Photogramm Remote Sens. 2018;146:151-160doi: 10.1016/j.isprsjprs.2018.09.010.
Wickham, J., Herold, N., Stehman, S. V., Homer, C. G., Xian, G., & Claggett, P. (2018). Accuracy assessment of NLCD 2011 impervious cover data for the Chesapeake Bay region, USA. ISPRS journal of photogrammetry and remote sensing : official publication of the International Society for Photogrammetry and Remote Sensing (ISPRS), 146151-160. https://doi.org/10.1016/j.isprsjprs.2018.09.010
Wickham, J, et al. "Accuracy assessment of NLCD 2011 impervious cover data for the Chesapeake Bay region, USA." ISPRS journal of photogrammetry and remote sensing : official publication of the International Society for Photogrammetry and Remote Sensing (ISPRS) vol. 146 (2018): 151-160. doi: https://doi.org/10.1016/j.isprsjprs.2018.09.010
Wickham J, Herold N, Stehman SV, Homer CG, Xian G, Claggett P. Accuracy assessment of NLCD 2011 impervious cover data for the Chesapeake Bay region, USA. ISPRS J Photogramm Remote Sens. 2018;146:151-160. doi: 10.1016/j.isprsjprs.2018.09.010. PMID: 30996518; PMCID: PMC6463313.
Copy Download .nbib Format: NLM
Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial.

Pathogens & immunity

Belaunzarán-Zamudio PF, Azzoni L, Canaday DH, Caro-Vega YN, Clagett B, Rassool MS, Rodriguez B, Sanne I, Sereti I, Sierra-Madero JG, Lederman MM.
PMID: 28736763
Pathog Immun. 2017;2(2):151-177. doi: 10.20411/pai.v2i2.181. Epub 2017 May 09.

BACKGROUND: We aimed to describe the mechanisms of immunological recovery and the effects of blocking CCR5 in patients starting ART with advanced HIV-infection.METHODS: This was a sub-study of a 48 week double-blind, clinical trial where patients starting ART with...

Cite
Belaunzarán-Zamudio PF, Azzoni L, Canaday DH, et al. Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathog Immun. 2017;2(2):151-177doi: 10.20411/pai.v2i2.181.
Belaunzarán-Zamudio, P. F., Azzoni, L., Canaday, D. H., Caro-Vega, Y. N., Clagett, B., Rassool, M. S., Rodriguez, B., Sanne, I., Sereti, I., Sierra-Madero, J. G., & Lederman, M. M. (2017). Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathogens & immunity, 2(2), 151-177. https://doi.org/10.20411/pai.v2i2.181
Belaunzarán-Zamudio, Pablo F, et al. "Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial." Pathogens & immunity vol. 2,2 (2017): 151-177. doi: https://doi.org/10.20411/pai.v2i2.181
Belaunzarán-Zamudio PF, Azzoni L, Canaday DH, Caro-Vega YN, Clagett B, Rassool MS, Rodriguez B, Sanne I, Sereti I, Sierra-Madero JG, Lederman MM. Immunologic Effects of Maraviroc in HIV-Infected Patients with Severe CD4 Lymphopenia Starting Antiretroviral Therapy: A Sub-Study of the CADIRIS Trial. Pathog Immun. 2017;2(2):151-177. doi: 10.20411/pai.v2i2.181. Epub 2017 May 09. PMID: 28736763; PMCID: PMC5518704.
Copy Download .nbib Format: NLM
Complete disruption of the esophagus; report of case.

The Journal of thoracic surgery

HIGGINSON JF, CLAGETT OT.
PMID: 18102749
J Thorac Surg. 1948 Dec;17(6):846-8.

No abstract available.

Cite
HIGGINSON JF, CLAGETT OT. Complete disruption of the esophagus; report of case. J Thorac Surg. 1948;17(6):846-8
HIGGINSON, J. F., & CLAGETT, O. T. (1948). Complete disruption of the esophagus; report of case. The Journal of thoracic surgery, 17(6), 846-8.
HIGGINSON, J F, and CLAGETT, O T. "Complete disruption of the esophagus; report of case." The Journal of thoracic surgery vol. 17,6 (1948): 846-8.
HIGGINSON JF, CLAGETT OT. Complete disruption of the esophagus; report of case. J Thorac Surg. 1948 Dec;17(6):846-8. PMID: 18102749.
Copy Download .nbib Format: NLM
Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection.

Perspectives in vascular surgery and endovascular therapy

Smith S, Clagett PG.
PMID: 17278317
Perspect Vasc Surg Endovasc Ther. 2006 Sep;18(3):267-8.

No abstract available.

Cite
Smith S, Clagett PG. Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. Perspect Vasc Surg Endovasc Ther. 2006;18(3):267-8
Smith, S., & Clagett, P. G. (2006). Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. Perspectives in vascular surgery and endovascular therapy, 18(3), 267-8.
Smith, Stephen, and Clagett, Patrick G. "Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection." Perspectives in vascular surgery and endovascular therapy vol. 18,3 (2006): 267-8.
Smith S, Clagett PG. Commentary. Human thrombin for treatment of pseudoaneurysms: comparison of bovine and human thrombin sonogram-guided injection. Perspect Vasc Surg Endovasc Ther. 2006 Sep;18(3):267-8. PMID: 17278317.
Copy Download .nbib Format: NLM
Rupture of the heart following myocardial infarction: data from a small hospital.

The American journal of the medical sciences

CLAGETT AH, BENGE JH, HOOKER JW.
PMID: 15410712
Am J Med Sci. 1950 May;219(5):513-6. doi: 10.1097/00000441-195005000-00006.

No abstract available.

Cite
CLAGETT AH, BENGE JH, HOOKER JW. Rupture of the heart following myocardial infarction: data from a small hospital. Am J Med Sci. 1950;219(5):513-6doi: 10.1097/00000441-195005000-00006.
CLAGETT, A. H., BENGE, J. H., & HOOKER, J. W. (1950). Rupture of the heart following myocardial infarction: data from a small hospital. The American journal of the medical sciences, 219(5), 513-6. https://doi.org/10.1097/00000441-195005000-00006
CLAGETT, A H, et al. "Rupture of the heart following myocardial infarction: data from a small hospital." The American journal of the medical sciences vol. 219,5 (1950): 513-6. doi: https://doi.org/10.1097/00000441-195005000-00006
CLAGETT AH, BENGE JH, HOOKER JW. Rupture of the heart following myocardial infarction: data from a small hospital. Am J Med Sci. 1950 May;219(5):513-6. doi: 10.1097/00000441-195005000-00006. PMID: 15410712.
Copy Download .nbib Format: NLM
Myocardial infarction.

Delaware medical journal

Clagett AH.
PMID: 5034744
Del Med J. 1972 Jun;44(6):151-7.

No abstract available.

Cite
Clagett AH. Myocardial infarction. Del Med J. 1972;44(6):151-7
Clagett, A. H. (1972). Myocardial infarction. Delaware medical journal, 44(6), 151-7.
Clagett, A H. "Myocardial infarction." Delaware medical journal vol. 44,6 (1972): 151-7.
Clagett AH. Myocardial infarction. Del Med J. 1972 Jun;44(6):151-7. PMID: 5034744.
Copy Download .nbib Format: NLM
Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ.
PMID: 33693561
Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212.

BACKGROUND: Inflammation is associated with end-organ disease and mortality for people with human immunodeficiency virus (PWH). Ruxolitinib, a Jak 1/2 inhibitor, reduces systemic inflammation for individuals without human immunodeficiency virus (HIV) and HIV reservoir markers ex vivo. The goal...

Cite
Marconi VC, Moser C, Gavegnano C, et al. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022;74(1):95-104doi: 10.1093/cid/ciab212.
Marconi, V. C., Moser, C., Gavegnano, C., Deeks, S. G., Lederman, M. M., Overton, E. T., Tsibris, A., Hunt, P. W., Kantor, A., Sekaly, R. P., Tressler, R., Flexner, C., Hurwitz, S. J., Moisi, D., Clagett, B., Hardin, W. R., Del Rio, C., Schinazi, R. F., & Lennox, J. J. (2022). Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 74(1), 95-104. https://doi.org/10.1093/cid/ciab212
Marconi, Vincent C, et al. "Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus." Clinical infectious diseases : an official publication of the Infectious Diseases Society of America vol. 74,1 (2022): 95-104. doi: https://doi.org/10.1093/cid/ciab212
Marconi VC, Moser C, Gavegnano C, Deeks SG, Lederman MM, Overton ET, Tsibris A, Hunt PW, Kantor A, Sekaly RP, Tressler R, Flexner C, Hurwitz SJ, Moisi D, Clagett B, Hardin WR, Del Rio C, Schinazi RF, Lennox JJ. Randomized Trial of Ruxolitinib in Antiretroviral-Treated Adults With Human Immunodeficiency Virus. Clin Infect Dis. 2022 Jan 07;74(1):95-104. doi: 10.1093/cid/ciab212. PMID: 33693561; PMCID: PMC8752257.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 29 entries